Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05854069
Collaborator
The Leona M. and Harry B. Helmsley Charitable Trust (Other), University of Utah (Other), University of California, Merced (Other), Children's Hospital Los Angeles (Other)
140
1
2
48.9
2.9

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: FAMS-T1D
  • Behavioral: Digital resources for diabetes
N/A

Detailed Description

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes
Actual Study Start Date :
Apr 4, 2023
Anticipated Primary Completion Date :
Jan 31, 2027
Anticipated Study Completion Date :
Apr 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: FAMS-T1D

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Behavioral: FAMS-T1D
FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
Other Names:
  • Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes
  • Behavioral: Digital resources for diabetes
    Quality digital resources about diabetes management provided upon enrollment and during the study.

    Placebo Comparator: Digital resources for diabetes

    All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

    Behavioral: Digital resources for diabetes
    Quality digital resources about diabetes management provided upon enrollment and during the study.

    Outcome Measures

    Primary Outcome Measures

    1. CGM frequency of use during the intervention period [Baseline and 6 months post-baseline]

      Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

    2. CGM frequency of use during the intervention period [Baseline and 6 months post-baseline]

      Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

    3. Gaps in CGM use [6 months post-baseline]

      Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

    Secondary Outcome Measures

    1. CGM behavioral responses during the intervention period [Baseline and 6 months post-baseline]

      Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

    2. Barriers to CGM use during the intervention period [Baseline and 6 months post-baseline]

      Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

    3. Barriers to CGM use during the intervention period [Baseline and 6 months post-baseline]

      Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

    4. CGM satisfaction during the intervention period [Baseline and 6 months post-baseline]

      Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

    Other Outcome Measures

    1. Data sharing during the intervention period [6 months post-baseline]

      Number of data sharing relationships, between groups; more is better

    2. Satisfaction with data-sharing relationships [6 months post-baseline]

      Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 24 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    PERSONS WITH DIABETES

    • Ages 18-24

    • Have a diagnosis of T1D and has been taking insulin for at least one year

    • Comfortable sending and receiving texts

    • Can speak, read, and write in English

    • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)

    • Using a continuous glucose monitor (CGM)

    SUPPORT PERSONS

    • Age 18 or older

    • Can speak, read, and write in English or Spanish

    • Comfortable sending and receiving texts

    Exclusion Criteria:

    PERSONS WITH DIABETES

    • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)

    • Plans to live outside the country during the study period

    SUPPORT PERSONS

    • Shares a phone with the person with diabetes

    • Plans to live outside of the country during the study period

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Utah Salt Lake City Utah United States 84112

    Sponsors and Collaborators

    • Vanderbilt University Medical Center
    • The Leona M. and Harry B. Helmsley Charitable Trust
    • University of Utah
    • University of California, Merced
    • Children's Hospital Los Angeles

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lindsay Mayberry, Principle Investigator, Vanderbilt University Medical Center
    ClinicalTrials.gov Identifier:
    NCT05854069
    Other Study ID Numbers:
    • 220847
    • G-2203-05822
    First Posted:
    May 11, 2023
    Last Update Posted:
    May 11, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lindsay Mayberry, Principle Investigator, Vanderbilt University Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 11, 2023